Copertina

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision?

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	L. A. A. P. Derikx, F. Hoentjen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
di: María José García, et al.
Pubblicazione: (2024)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
di: María José García, et al.
Pubblicazione: (2024)

A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis
di: Anthony Croft, et al.
Pubblicazione: (2024)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
di: Monica E. W. Derks, et al.
Pubblicazione: (2025)

Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis
di: Manuel Barreiro‐de Acosta, et al.
Pubblicazione: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
di: Vibeke Strande, et al.
Pubblicazione: (2024)

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
di: Giammarco Mocci, et al.
Pubblicazione: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
di: Tomohiro Fukuda, et al.
Pubblicazione: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis‐A delicate balance of efficacy and safety
di: Shintaro Sagami, et al.
Pubblicazione: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively?
di: David Laharie
Pubblicazione: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply
di: Remo Panaccione
Pubblicazione: (2024)

Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
di: María Chaparro, et al.
Pubblicazione: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
di: Matthias Lenfant, et al.
Pubblicazione: (2024)

Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing
di: Tomohiro Fukuda, et al.
Pubblicazione: (2024)

Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study
di: Merle Claßen, et al.
Pubblicazione: (2024)

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
di: Shintaro Akiyama, et al.
Pubblicazione: (2024)

Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people
di: Shuyao Song, et al.
Pubblicazione: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
di: David Bergman, et al.
Pubblicazione: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
di: C. M. Fernández‐Rodríguez, et al.
Pubblicazione: (2024)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
di: Stephanie A. Vuijk, et al.
Pubblicazione: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis
di: Fang Yan, et al.
Pubblicazione: (2024)

Editorial: Solving the acute kidney injury puzzle in alcohol‐associated hepatitis—Challenges and insights
di: Vishnu Girish, et al.
Pubblicazione: (2024)

Editorial: Vibrating capsule for severe chronic idiopathic constipation—Severity lies in the eye of the beholder
di: Sanskriti Varma, et al.
Pubblicazione: (2024)

Editorial: ARFI‐based techniques are better than VCTE for diagnosing advanced fibrosis in severe obesity
di: Davide Roccarina, et al.
Pubblicazione: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
di: Abhinav Vasudevan, et al.
Pubblicazione: (2024)

Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
di: Neil Chanchlani, et al.
Pubblicazione: (2024)

Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis?
di: Ling Yang, et al.
Pubblicazione: (2024)

Editorial: Shorter course of intravenous terlipressin in acute variceal bleeding—the promise, controversies and future directions. Author's reply
di: Sagnik Biswas, et al.
Pubblicazione: (2024)

Editorial: Proton Pump Inhibitors and the Changing Face of Spontaneous Bacterial Peritonitis
di: S. Quickert, et al.
Pubblicazione: (2026)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
di: Abdulrahman Ismaiel
Pubblicazione: (2026)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?
di: Guilherme Grossi Lopes Cançado
Pubblicazione: (2024)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows?
di: J. M. B. W. Vos, et al.
Pubblicazione: (2025)

Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study
di: Carl Eriksson, et al.
Pubblicazione: (2024)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
di: L. Aceituno, et al.
Pubblicazione: (2026)

Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
di: Ann T. Ma, et al.
Pubblicazione: (2024)

Editorial: Cardiometabolic criteria matters inMASLD
di: Margaret L. P. Teng, et al.
Pubblicazione: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2024)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2025)

The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease
di: Sebastiaan ten Bokkel Huinink, et al.
Pubblicazione: (2025)